Caricamento...
Biologics in asthma management – Are we out of breath yet?
The biologics authorized for the add-on therapy of severe asthma are monoclonal antibodies (mAbs). Before they are considered for therapy intensification, the patient’s asthma endotype is determined on the basis of phenotypic characteristics. So far, 5 biologics are available that target the signali...
Salvato in:
| Pubblicato in: | Allergol Select |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dustri-Verlag Dr. Karl Feistle
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7890935/ https://ncbi.nlm.nih.gov/pubmed/33615123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5414/ALX02192E |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|